Related Experiment Video
Updated: Jul 8, 2026

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
Published on: August 14, 2018
Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity
Shinya Oishi1, Saori Ito, Hiroki Nishikawa
1Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan. soishi@pharm.kyoto-u.ac.jp
Abstract:
Reported herein are the design, biological activities, and biophysical properties of a novel HIV-1 membrane fusion inhibitor. alpha-Helix-inducible X-EE-XX-KK motifs were applied to design an enfuvirtide analogue 2 that exhibited highly potent anti-HIV activity against wild-type HIV-1, enfuvirtide-resistant HIV-1 strains, and an HIV-2 strain in vitro. Indispensable residues for bioactivity of enfuvirtide, including the residues interacting with the N-terminal heptad repeat and the C-terminal hydrophobic residues, were identified.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Protein-protein Interfaces
Protein-Protein Interfaces
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release

